Terms and Conditions

In compliance with the obligations set forth in Law No. 7472 on the Promotion of Competition and Effective Consumer Protection, as well as the related laws applicable in each of the “Participating Countries,” which will be identified below, and the duties associated with the disclosure of objective and truthful information in advertising concerning offers and promotions, in order to ensure that consumers are not affected by misleading advertising or that unfair competition does not occur, ASTRAZENECA CAMCAR COSTA RICA SOCIEDAD ANÓNIMA, a company organized and existing under the laws of the Republic of Costa Rica, with legal entity identification number 3-101-504452 (the “Organizer” or AstraZeneca), hereby publicly announces, for all applicable legal purposes, that the Rules of the Disfruto mi Salud Program (the “Rules”) shall be governed in accordance with the laws of Costa Rica and the following clauses:

FIRST – PURPOSE AND GENERAL PROVISIONS:

The “Disfruto mi Salud” Program, hereinafter referred to as the Program, is intended to support adherence to medical treatments for various diseases in the fields of BioPharma and Specialty Care, by offering benefits to patients who use AstraZeneca products. The benefits are detailed in these Rules and include, but are not limited to, providing information on the management of the medical condition and sending digital and physical educational materials, as well as other types of assistance that promote compliance with and adherence to medical treatment, with the objective of improving patients’ quality of life.

These Rules establish and clarify the conditions under which the Program shall operate. The provisions set forth herein shall be mandatory for patients and organizers. Participation in the Program shall be deemed to constitute the participant’s acknowledgment and acceptance of the conditions and limitations established in these Rules. Participation in the Program implies the patient’s decision to comply with and abide by these Rules and the decisions of the Organizer, which shall be final and binding in all matters related to the Program. Any violation of these Rules, or of the procedures or systems established for the implementation of the Program, shall result in the immediate exclusion of the patient and/or the revocation of the corresponding benefits.

SECOND – THE ORGANIZER:

ASTRAZENECA CAMCAR COSTA RICA S.A. is the company organizing the Program and is solely responsible for it. The company may, in turn, engage third parties of its choice to administer and/or provide some of the services that are part of the Program.

THIRD – PATIENTS:

Patients whose respective physicians prescribe any of the Participating BioPharma and Specialty Care Products detailed in Appendix I, which forms an integral part of these Rules, may participate in the Program, provided that they meet all of the following requirements:

I.- Be over eighteen years of age; or, in the case of minors, they may participate through the person(s) who have parental authority or legal guardianship over the minor.

II.- Wish to participate in the Program.

III.- Register for the Program through the telephone numbers or website designated by the Organizer for such purpose, accepting the conditions established in these Rules.

FOURTH – TERMS:

The validity period of the Program and the Rules shall be defined as follows:

El Organizador podrá ampliar o reducir dicho plazo unilateralmente en cualquier momento.

QUINTA – GEOGRAPHIC COVERAGE:

The Program will have coverage in Central America and the Caribbean, specifically for each product in the following jurisdictions

The Program is valid at participating pharmacies within the aforementioned jurisdictions that are duly affiliated with the Program. It shall be the responsibility of Program patients to verify that the pharmacy where they purchase participating products is duly affiliated with the Program.

SIXTH – COMMUNICATION CHANNELS:

Patients may learn more about the Program through the following telephone numbers:

Also, patients may consult the most up-to-date version of these Regulations at https://celebratelifeprogram.com/faq/#reglamento-section/, as well as all information related to the Program on the website https://celebratelifeprogram.com/. Any questions or comments regarding the Program, participating pharmacies, or any other matter related to the Program may be directed to the telephone numbers listed in this clause.

SEVENTH – PATIENT RESPONSIBILITIES:

Patients enrolled in the Program are responsible for:

· Present a valid identification document, as applicable, at the time of enrollment and each time a purchase is made, a redemption is requested, or a benefit offered through the Program is requested.

· Have a valid medical prescription for the purchase of the medication, which must be provided at the time of enrollment in the Program. The name appearing on the prescription must match the name verified on the identification document provided.

· Select their treating physician at the time of enrollment and, if the physician cannot be found in the list provided, contact the call center for assistance.

· The Organizer shall not be responsible for the replacement of redemptions or benefits requested without the authorization of the patient who owns them.

· Request that the pharmacy record the transaction in accordance with the procedures established by the Program.

· Report, through the channels made available by the Organizer, any Adverse Event (AE), understood as any unwanted medical condition that arises following the use of a medication or the performance of a medical test. Patients have been informed that they may report any AE related to an AstraZeneca product they have used to their treating physician, where such AE may have been caused by the use of a product of the Organizer.

· Strictly comply with the treating physician’s instructions, including, but not limited to, the prescribed medication schedules and dosages. Therefore, the Organizer shall not be liable for the manner in which patients use or consume products associated with the Program.

EIGHTH – PROHIBITIONS:

· The use of a personal identification document to register group purchases or purchases made on behalf of third parties is not permitted.

· The transfer of purchases, redemptions, and/or benefits to third parties is prohibited.

· Registering purchases personally, or having them registered by the pharmacy more than 48 hours after the purchase date, is prohibited.

NINTH – BIOPHARMA PROGRAM PATIENT PROCESS:

To access the loyalty benefits, patients must:

· Have a treating physician and provide an image of their valid identification document. If requested, they must present the physical document for validation purposes.

· Have a valid medical prescription for one of the products participating in the Program. Enrollments without a valid prescription will not be accepted. The name stated on the prescription must match the patient’s name and personal identification.

· Enroll in the Program through the telephone numbers or website referenced in Clause Six of these Terms and Conditions.

· Purchase the prescribed product at one of the pharmacies participating in the Program. Information regarding participating pharmacies may be obtained by calling the Program’s telephone number or visiting its website.

· Present their identification number when purchasing Products or receiving any benefit.

· Request that the pharmacy register the purchase at the time it is made. Such purchase shall remain valid for one (1) year, after which, if it has not been used for a redemption, it will expire and be removed from the patient’s accumulated purchases.

·  In the case of BioPharma products, patients must comply with the required number of registered purchases as set forth in Appendix I, Section 1.1 – Table of BioPharma Products Participating in the Program and Redemption Parameters.

· Request a redemption, when applicable, at the pharmacies participating in the Program. Appendix I, Section 1.1 – Table of BioPharma Products Participating in the Program and Redemption Parameters establishes the number of redemptions that a patient may make per calendar year. Even if a patient has accumulated a sufficient volume of purchases to request additional free product, the patient may not request more free product than the amount established in Appendix I. Any patient may request a review of their case by the Organizer by submitting any documentation deemed necessary. The Organizer reserves the right to approve exceptions when, at its sole discretion, the evidence submitted justifies such an exception and there is medical support for exceeding the maximum limits established in Appendix I.

TENTH – SPECIALTY CARE PROGRAM BENEFITS:

At the Organizer’s discretion and depending on the product, medical prescription, and country, patients enrolled in the Program may receive the following benefits:

·  Additional services provided by specialists such as psychologists, nutritionists, physical therapists, etc., either virtually or in person.

·  Assessment of patient needs for subsequent support.

·  Provision of educational materials.

·  Medication reminders.

·  Appointment reminders.

·  Adverse Event Reporting

·  Satisfaction survey regarding the services provided by the Patient Support Programme.

·  Group workshops and talks for patients

·  A 1+1 or 2+1 benefit, as applicable, for private sector patients (tailored therapies). Tailorade Therapies – Celebrate life 2023

·  Co-payment benefit for patients with private insurance Co Payment Regulations – Celebrate life 2023

SECTION 11 – LIABILITY OF THE ORGANISER:

The Organiser shall be liable only to the extent set out in these Rules.

The Organiser shall consider as a beneficiary of the Programme’s benefits – including the right to the benefit or redemption specified in these Rules – any individual who is registered with the Programme and who meets all the requirements set out in these Rules.

The Organiser, its affiliates, representatives and directors shall under no circumstances be liable for any damages that may be suffered by a person who consumes the product provided as part of the scheme without having been advised to do so by a doctor; accordingly, each patient shall be solely responsible for the use made of the product received as part of the scheme; furthermore, the patient releases the Organiser from any liability that may arise in cases where the relevant pharmacy misuses the product provided for use within the Programme. The Organiser shall not be obliged to replace the benefit or product offered as a reward with any other product, good or service, nor to apply it towards discounts or other types of benefits. To gain access to the benefit or reward, the patient must comply with all the requirements set out in these Rules. The products offered as rewards are indivisible, non-transferable and non-exchangeable for any other product and/or benefit. Similarly, the Organiser accepts no liability for damages caused by unforeseeable circumstances, force majeure or the acts of third parties, nor for any failure by patients to comply with the provisions of these Rules.

The Patient understands and acknowledges that they have been informed that the Programme is run by a third party contracted by AstraZeneca, and that the Programme may be suspended or terminated at any time; this decision will not affect their treatment or their relationship with their doctor, and therefore the Patient shall have no grounds for making any claims against AstraZeneca.

ARTICLE 12 – AMENDMENTS:

The Organiser reserves the right to amend the Programme, the list of participating products, benefits, or any other feature, document, process or mechanism of the Programme at any time, with the sole obligation to publicise such changes on the Programme’s website and, where necessary, to reflect such changes in these Terms and Conditions.

ARTICLE 13 – SUSPENSION OF THE PROGRAMME:

The Organiser reserves the right to suspend the Programme at any time, either in part or in full, temporarily or permanently. Furthermore, the Organiser reserves the right to cancel any patient’s membership of the Programme should it be established that benefits have been allocated or claimed fraudulently. Any deception, fraud or forgery that hinders the normal running of the Programme, and any actions which, in the Organiser’s judgement, are illegal or prohibited under the terms set out herein and/or applicable legislation, and which may cause harm to the Programme or its organisers, may be prosecuted by the means provided for in the relevant laws.

SECTION 14 – LEGAL ENTITIES OR INSTITUTIONS:

Legal entities are not permitted to participate in the Programme. Should any social welfare institution or organisation that assists patients in obtaining their medicines wish to participate in the Programme or to pass on the Programme’s benefits to their patients, they may contact the Organiser. The Organiser reserves the right to decide whether or not to provide the Programme’s benefits, in whole or in part, to organisations, foundations or institutions of this kind.

SECTION FIFTEEN – OWNERSHIP OF INFORMATION AND INFORMED CONSENT

Patients authorise and consent to access to their information and its inclusion in databases located in any country worldwide, where the Organiser may hold such data, for the duration of the Programme and for a period of up to three (3) years following the end of the Programme, and further authorise the use of such information by the Organiser for the purposes described below.

·       To enable patient participation in the programme, as well as its proper management, administration, operation and monitoring.

·       To share patient information exclusively with: (i) the patients themselves, upon their express request; (ii) the treating doctors, for the purposes of monitoring, follow-up and continuity of treatment; (iii) family members or trusted individuals previously designated by the patient; and (iv) third parties who, in the Organiser’s reasonable judgement, need to be made aware of such information, solely where such knowledge is necessary and beneficial to the patient and/or their treatment, whilst ensuring at all times compliance with applicable legislation on the protection of personal data and confidentiality.

·       To liaise with a multidisciplinary care team to ensure a comprehensive approach and appropriate management of the User’s medical condition;

·       Permitir el monitoreo del tratamiento

·       To be contacted by AstraZeneca via any means (email, SMS, WhatsApp) to take part in testimonial or awareness-raising campaigns;

·       To be invited to educational events relating to your medical condition, with the aim of enhancing your knowledge and management of it, as well as for commercial prospecting communications.

Please also note that, should a patient remain inactive within the Programme for a continuous period of three (3) years, their personal data will be deleted from the Programme’s databases. In such cases, in order to rejoin the Programme, the patient must complete a new registration process via Celebrate life.

The Organiser will not have direct access to personal information that could identify patients. For the purposes of the Programme, such information will be managed exclusively by third parties engaged by the Organiser for that purpose. Consequently, the Organiser will only have access to anonymised data, without the possibility of identifying patients either directly or indirectly.

The Patient may access their personal data upon request, in accordance with the procedures set out in these Regulations.

The Patient states that it is in their interest to participate in the Programme in order to receive all or part of the benefits available under the Programme, and that they understand and acknowledge that the activities carried out as part of the Programme do not replace the diagnosis, recommendations and/or treatments prescribed by their doctor. Similarly, the Patient understands that the Programme aims to guide and inform Patients, their families and the healthcare team on the appropriate use of prescribed medicines, to provide information and education on the condition, and to provide information and education on the disease.

The Patient understands and acknowledges that they have been informed that the Programme is run by a third party contracted by AstraZeneca, and that the Programme may be suspended or terminated at any time; this decision will not affect their treatment or their relationship with their doctor, and therefore the Patient shall have no grounds for making any claims against AstraZeneca.

In addition, patients authorise the Organiser to send text messages, emails, post or communications via any other available channel relating to the Programme to the mobile phone number and/or addresses recorded in the database; and to make calls for the following purposes:

• Communicate any significant changes that may affect the patient – Verify any purchases or exchanges recorded in the patient’s name.
• Update and/or verify the patient’s details.
• To coordinate the provision of any benefit requested by the patient.
• Otros temas relacionados con el Programa.

Patient data will be stored and maintained in accordance with the provisions of these Regulations, as well as any specific informed consent forms signed by the patient. Without prejudice to the foregoing, for the purposes of these Regulations, it is hereby stated that:

·       The data will be held by ASTRAZENECA CAMCAR COSTA RICA SOCIEDAD ANONIMA, with offices at Roble Corporate Centre, 5th floor, San Rafael de Escazú, corporate registration number 3-101-504452, which, for the purposes of the Programme, acts as the data controller for the processing of personal data.

·       The Organiser will use the patient’s personal data for the purposes of this Programme as set out in these terms and conditions, to which the patient hereby gives their consent.

The Patient may, at any time, exercise their rights of access, rectification, erasure and objection (ARCO) in relation to their personal data, in accordance with the Law on the Protection of Individuals with regard to the Processing of Personal Data, Law No. 8968 of the Republic of Costa Rica. To this end, the Organiser provides the following contact channels:

E-mail:

·       Biopharma program: contacto@disfrutomisalud.com

·       Highly Specialised Programme: contacto.oncologia@disfrutomisalud.com 

Call center:

Should a patient request that their details be removed from the contact lists, they may, at the Organiser’s discretion, lose the right to participate in the Programme, including the right to any outstanding redemptions as at that date.

The patient confirms that they have received all the information required in accordance with Article 5 et seq. of the Law on the Protection of Individuals with regard to the Processing of Personal Data of the Republic of Costa Rica, No. 8968.

SECTION 16 – APPLICABILITY OF THE REGULATIONS:

These Regulations shall apply equally to all patients on the Programme. Failure to comply with any provision of these Regulations may, at the Organiser’s discretion, result in the patient’s exclusion from the Programme and the loss of all benefits yet to be redeemed.

ARTICLE 17 – RELATIONSHIP BETWEEN THE PARTIES:

No provision of the Programme shall be construed as creating a relationship between the parties other than that arising in the ordinary course of business through participation in the Programme. No patient or beneficiary of the Programme’s benefits shall, by virtue of that status, acquire the status of employee, representative or agent of the Organiser. The relationship between the parties shall cease in its entirety upon fulfilment of the obligations set out in these Rules.

ARTICLE 18 – PUBLICATION OF THESE REGULATIONS:

A copy of these Regulations will be available to all patients on the Programme at the following web address:  https://celebratelifeprogram.com/regulation-costa-rica/

Should you have any queries or questions regarding the scope and interpretation of these Regulations, or if you wish to request a digital copy of them, please contact the Organiser by telephone or via the website provided for this purpose. Any information provided does not alter or amend these Regulations.

Produced by AstraZeneca CAMCAR Costa Rica S.A., Plaza Roble Corporate Centre, Piso 5, Escazú, San José, Costa Rica. Teléfono: (506) 2201-3400. Apdo. 993-1220 Escazú. www.astrazeneca.com para AstraZeneca CAMCAR, S.A. Para reportar Evento adverso, queja de calidad o solicitud de información médica hacer clic en el siguiente link: https://contactazmedical.astrazeneca.com/ CC-16673/ mayo 2028